west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "王丽春" 14 results
  • 吲哚氰绿清除试验在肝病中的应用进展

    目前评价肝脏功能的检测方法较多,吲哚氰绿清除试验作为动态评价肝脏功能的检测手段之一,能够全面地反映肝脏相关情况,为患者的诊治及预后评估提供一定依据。本文就吲哚氰绿清除试验在肝硬化、肝衰竭、肝切除术以及肝移植领域的应用进展进行了综述。

    Release date:2017-03-27 11:42 Export PDF Favorites Scan
  • 冠状病毒的研究进展

    Release date:2020-09-27 06:38 Export PDF Favorites Scan
  • 肝纤维化无创性诊断的研究进展

    肝纤维化是慢性肝病的重要病理阶段,也是进一步向肝硬化发展的主要中间环节,目前的研究认为肝纤维化是可逆的,而肝硬化是不可逆的。因此肝纤维化的早期诊断和及时干预对于疾病的进展及预后的改善极为重要。近年来肝纤维化的诊断手段与技术方面得到了很大的发展,尤其是无创性诊断方法。现对肝纤维化无创性诊断的研究进展作一综述。

    Release date:2021-06-23 07:35 Export PDF Favorites Scan
  • 慢性乙型肝炎核苷类似物抗病毒治疗应答的影响因素

    我国乙型肝炎病毒感染率高,慢性乙型肝炎的治疗目标是最大限度地长期抑制乙型肝炎病毒,延缓和减少疾病进展及肝脏失代偿、肝硬化、肝细胞癌等的发生,从而改善生活质量和延长存活时间。随着干扰素及核苷类似物两大类抗病毒治疗的进展,发现不同的患者在治疗疗效上有很大差异,研究认为,核苷类似物抗乙型肝炎病毒治疗的疗效主要受药物、病毒及宿主3个方面因素的影响。

    Release date: Export PDF Favorites Scan
  • 双下肢及颜面部水肿为首发表现的POEMS综合征一例

    Release date: Export PDF Favorites Scan
  • 微 RNA 在乙型肝炎相关疾病中作用研究进展

    乙型肝炎病毒(hepatitis B virus,HBV)感染是造成肝纤维化、肝衰竭和肝癌的主要原因。微 RNA(microRNA,miRNA)在 HBV 慢性感染状态下出现异常表达。部分表达异常的 miRNA 可以通过活化肝星状细胞或产生胶原蛋白来促进肝纤维化过程;也可以通过诱导肝细胞短期内大量坏死或凋亡来加速肝衰竭进展;亦可以通过上调癌基因或下调抑癌基因表达促进癌症的发生与发展。该文初步探讨了 miRNA 在肝纤维化、肝衰竭、肝癌中的作用。

    Release date:2017-11-24 10:58 Export PDF Favorites Scan
  • Pulmonary abscess caused by Rhodococcus equi : a case report and literature review

    ObjectiveTo examine the characteristics of Rhodococcus equi (R. equi) infection for better awareness of this disease.MethodsThe clinical data of a patient with pulmonary abscess caused by R. equi after renal transplantation were reported. We also reviewed the reports of infections caused by R. equi.ResultsThe clinical manifestations and laboratory examination of the patient were consistent with the characteristics of R. equi infection. The growth of R. equi was found in sputum and blood culture. The follow-up data showed that the treatment was effective. Literature search identified 23 similar patients. In all the 24 patients (containing this one), the time of infection after renal transplantation ranged from 4 months to 11 years. There were 21 patients with cumulative pulmonary infection, and 10 patients had a clear epidemiological history of direct or indirect contact with horses. Eighteen patients improved after regular antibacterial treatment or surgical treatment.ConclusionsOpportunistic infections caused by R. equi mainly affect transplant recipients and other patients with lower immunity. Infections caused by R. equi may affect many organ systems with various manifestations. The optimal therapy is not established due to the rarity of this infection. Clinicians should select antibiotic agents rationally based on antimicrobial susceptibility testing and treatment response of patients.

    Release date: Export PDF Favorites Scan
  • Domestic Cefepime Injection for Acute Bacterial Lower Respiratory Tract Infection: A Randomized Single-blind Controlled Clinical Trial

    Objective To evaluate the clinical efficacy and safety of domestic cefepime in the treatment of acute bacterial lower respiratory tract infection. Methods A randomized, single-blind, controlled clinical trial was performed. The positive control was imported cefepime. The dosages of cefepime were 1g for moderate infection and 2g for severe infection, twice a day intravenously. The duration of the treatment was 7-10 days. Results Thirty-one patients were enrolled in the trial, of whom 30 were evaluable (15 in the triagroup and 15 in the control group). No significant differences were observed between the trial group and the control group with respect to the cure rate (40% vs. 27%), the effective rate (80% vs. 87%), the bacterial clearance rate (92% vs. 100%), and the incidence of adverse drug reactions (12.5% vs. 13%) (Pgt;0.05). Conclusion Domestic cefepime injection is effective and safe in the treatment of acute bacterial lower respiratory tract infection.

    Release date:2016-09-07 02:16 Export PDF Favorites Scan
  • Jiuweirougan Granule in the Treatment of Chronic Hepatitis with Hepatic Fibrosis: A Double-Blind Randomized Controlled Trial

    Objective To assess the effectiveness and safety of Jiuweirougan granule in the treatment of chronic hepatitis with hepatic fibrosis. Methods A double-blind, double dummy and randomized controlled method was adopted. Forty-six patients were selected by using the inclusion and exclusion criteria and were randomizedly allocated to the treatment group (n=23, Jiuweirougan 10 g, twice a day) and the control group (n=23, treated with Biejiaruangan 4 pills, three times a day). The duration of treatment for both groups lasted for 6 months. Results Two patients in the treatment group dropped out halfway through the study, while one patient in the control group was withdrawal for irregular treatment. Analysis according to intention-to-treat (ITT) and per-protocol (PP) was conducted. In the treatment group, the effective rates of TCM (Traditional Chinese Medicine) on the syndrome were 82.61% (19/23) (ITT) and 90.48% (19/21) (PP), while in the control group, there were 86.96% (20/23) (ITT) and 86.36% (19/20) (PP). There was no significant difference between the two groups (P>0.05). The improvement rate of serum parameters in the treatment group such as hyaluronic acid (HA), type Ⅲ procollagen (PCⅢ), type Ⅳ collagewn (CⅣ) and laminin (LN) were 28.57% (6/21), 23.81% (5/21), 28.57% (6/21) and 4.76% (1/21), respectively, while in control group, the rates were 36.37% (8/22),13.64% (3/22), 36.37% (8/22) and 9.09% (2/22), respectively. No significant difference was seen between the two groups (P>0.05). ITT and PP analysis revealed similar results. No obvious adverse effects were noted. Conclusion Jiuweirougan granule may improve chronic hepatitis with fibrosis, and its effect is equal to that of Biejiaruangan. No obvious toxic-adverse effects were seen.

    Release date:2016-09-07 02:27 Export PDF Favorites Scan
  • 艾滋病并发播散性非结核性分枝杆菌感染一例

    Release date:2016-09-08 09:13 Export PDF Favorites Scan
2 pages Previous 1 2 Next

Format

Content